MIRM vs SRRK
MIRM: Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic liver disease and viral hepatitis. SRRK: Scholar Rock develops myostatin-inhibiting monoclonal antibodies to treat rare neuromuscular diseases like spinal muscular atrophy, with lead candidate apitegromab anticipated for regulatory approval in 2026.
Side-by-side fundamentals
| Metric | MIRM | SRRK | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $100.65 | $52.92 | |
| Market cap as of 2026-08-10 | $6.5B | $6.4B | |
| PEG as of 2026-08-10 | -0.01 | -1.06 | SRRK lower |
| Net margin as of 2026-08-10 | -139.2% | -237.0% | MIRM higher |
| Gross margin as of 2026-08-10 | +81.7% | n/a | |
| Operating margin as of 2026-08-10 | -136.8% | -231.8% | MIRM higher |
| ROE as of 2026-08-10 | -289.3% | -159.1% | SRRK higher |
| ROA as of 2026-08-10 | -96.5% | -86.6% | SRRK higher |
| Debt / equity as of 2026-08-10 | 1.28 | 0.77 | SRRK lower |
| Revenue growth (YoY) as of 2026-08-10 | +44.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +89.1% | n/a | |
| Beta as of 2026-08-10 | 0.60 | 0.58 | |
| 1-year return as of 2026-08-07 close | +68.3% | +68.6% | SRRK higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.